Common Stock, $0.00001 par value per share
- Symbol
- GUTS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Fractyl Health, Inc.
GUTSNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Fractyl Health, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates →Company context
Fractyl is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company’s lead product candidate, Revita, is an endoscopic procedural therapy in pivotal development for post-GLP-1 weight maintenance. Fractyl’s goal is to change the course of metabolic disease, advancing treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
Current securities
Recent company filings
- Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsOct 22, 2026
- Regulation FD Disclosure · Other EventsOct 16, 2026
- Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 1, 2026
- Submission of Matters to a Vote of Security HoldersSep 24, 2026
- 4 filingSep 16, 2026
Registered securities in this filing
Fractyl Health, Inc. · 8-K · Filed 2026-08-10
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 10, 2026, Fractyl Health, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly provided by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 guts-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations - the first randomized evidence of durable, drug-free weight maintenance One-year open-label REVEAL-1 Cohort data provide real-world evidence of durable weight maintenance, with patients maintaining approximately 78% of their prior GLP-1-induced weight loss after a single Revita procedure REMAIN-1 Pivotal Cohort topline data on track for early Q4 2026, paving the way for potential FDA De Novo submission in post-GLP-1 weight maintenance in late Q4 2026 Cash runway guidance into early 2027, beyond anticipated Pivotal data readout and FDA De Novo Submission Conference call today at 4:30 p.m. ET BURLINGTON, Mass., August 10, 2026 (GLOBE NEWSWIRE) - Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced se…
Open exhibit ↗